Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials

Journal of Clinical Oncology

Volumn 19, Issue 2, 2001, Pages 558-567

  Major, P ^a   Lortholary, A ^a   Hon, J ^a   Abdi, E ^a   Mills, G ^a   Menssen, H D ^a   Yunus, F ^a   Bell, R ^a   Body, J ^a   Quebe Fehling, E ^a   Seaman, J ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME;

EID: 0035863508     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.2.558     Document Type: Article

References (36)

1. Metabolic emergencies
2. Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and nonhumoral groups
3. The hypercalcemia of cancer: Clinical implications and pathogenic mechanisms
4. Hypercalcemia
5. Cancer-associated hypercalcemia: Morbidity and mortality - Clinical experience in 126 treated patients
6. Bisphosphonates as cancer drugs
7. Mechanisms of bone metastasis
8. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate
9. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: A randomized comparison between a 3-day treatment and single 24-hour infusions
10. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcemia caused by cancer
11. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia
12. Treatment of cancer-associated hypercalcemia: Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone
13. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages
14. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate [APD]) as single shot treatment of hypercalcemia
15. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate
16. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
17. A dose-finding study of zoledronate in hypercalcemic cancer patients
18. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases
19. A phase I, open label, dose-ranging, trial of intravenous-bolus zoledronic acid, a novel bisphosphonate, in cancer patients with osteolytic bone lesions
20. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and bone
21. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia
22. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy
23. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia
24. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia
25. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models
26. Comparative tolerability of drug therapies for hypercalcaemia of malignancy
27. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
28. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
29. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
30. Bisphosphonates inhibit prostate and breast carcinoma cell invasion, but not tumor cell migration, through a mechanism independent of apoptosis induction
31. Bisphosphonates inhibit the platelet-aggregating activity of tumor cells, a process involved during hematogenous dissemination of metastatic cells
32. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
33. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses
34. Bisphosphonates inhibit breast cancer cell proliferation